Philip J Mease MD

Director, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and Clinical Professor University of Washington School of Medicine

Join to view full profile

1101 Madison StSte 1000Seattle, WA 98104
Phone+1 206-386-2001
Fax+1 206-386-2083

Dr. Mease is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mease's full profile Already have an account?

Education & Training

University of WashingtonFellowship, Rheumatology, 1981 - 1982
University of WashingtonResidency, Internal Medicine, 1977 - 1981
Stanford University School of MedicineClass of 1977

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

WA State Medical License 1978 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

LIfetime Achievement Award National Psoriasis Foundation, 2019
America's Top Doctors Castle Connolly, 2008-2014
Super Doctor SuperDoctors.com

Clinical Trials

Rituxan With or Without Methotrexate in Psoriatic Arthritis
COMPLETED
PHASE1
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
COMPLETED
PHASE2
Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301
TERMINATED
NA

Publications & Presentations

PubMed

Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomise...
Désirée van der Heijde, Philip J Mease, Carle Paul, Frank Behrens, Laure Gossec
Annals of the Rheumatic Diseases. 2026-08-06
Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Resul...
Alexis Ogdie, Joseph F Merola, Philip J Mease, Christopher T Ritchlin, Jose U Scher
Arthritis & Rheumatology. 2026-08-01
Who Achieves Minimal and Very Low Disease Activity in Psoriatic Arthritis? An Analysis of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Alexis Ogdie, Chao Song, Nicole Middaugh, Maya Marchese, Melissa Eliot
The Journal of Rheumatology. 2026-08-01

Journal Articles

Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials
Alice Gottlieb, Philip Mease, Arthritis Care & Research
Dual Inhibition of Tumour Necrosis Factor and Interleukin-17A with ABT-122: Open-Label Long-Term Extension Studies in Rheumatoid Arthritis or Psoriatic Arthritis
Philip Mease, MD, Rheumatology
Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients with Psoriatic Arthritis: A Prospective Cohort Study
Philip Mease, MD, Arthritis Care & Research

Lectures

24-Week Results From the RAPID-PsA Study
Annual European Congress of Rheumatology 2012, Berlin, Germany
24-Week Results From the RAPID-PsA Study
European League Against Rheumatism, Annual European Congress of Rheumatology 2012, Berlin, Germany

Authored Content

Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialOctober 2020

Press Mentions

Janus Kinase vs. TNF Inhibitors for Noninflammatory PainApril 8th, 2026
QD Clinic: CAR-T Cell Therapy for Lupus SaveDecember 4th, 2025
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (Deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus ErythematosusOctober 27th, 2025